Image source: The Motley Fool.
Jounce Therapeutics, Inc. (JNCE)
Q4Â 2019 Earnings Call
Feb 27, 2020, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good morning ladies and gentlemen and welcome to the Jounce Therapeutics Fourth Quarter and Full Year 2019 Earnings Conference Call. [Operator Instructions].
I will now turn the call over to your host Komal Joshi with Jounce Therapeutics. Please go ahead.
Komal Joshi -- Head of Investor Relations
Thank you operator. Good morning and welcome to the Jounce Therapeutics Quarter and Full Year 2019 Financial Results Conference Call. This morning we issued a press release which outlines the topics that we plan to discuss today. The release is available in the Investors and media section of our website at www.jouncetex.com. Speaking on today's call will be our CEO and President Dr. Rich Murray who will discuss our pipeline progress and key milestones for 2020 followed by our CMO Dr. Beth Trehu who will provide an update on our clinical activities. And lastly our CFO Kim Drapkin will review our full year 2019 financial results and 2020 guidance. We will then open the call for your questions.
Before we begin I would like to remind everyone that today's discussion will include statements about our future expectations plans and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including the risk factors discussed in our SEC filings. In addition any forward-looking statements represent our views only as of today February 27 2020 and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future we specifically disclaim any obligation to do so even if our views change.
With that I will now turn the call over to Rich.
Richard Murray, Ph.D. -- Chief Executive Officer and President
Thanks Komal and good morning everyone. As we reflect on 2019 I'd like to note the meaningful advancements Johns has made to further progress our growing IO pipeline toward several key milestones that we set forth in early 2019. That progress stems from our translational science platform driving new IO therapies to the clinic as well as analyzing patient samples from our clinical trials to inform new science-driven development paths. The latter is best illustrated by our lead Phase II program vopratelimab which represents what we believe will be necessary to make a meaningful impact for patients who are not benefiting from today's IO therapies. For vopra we made significant progress over the course of 2019. First the introduction of our two vopra development paths. Based on the results of extensive reverse translation allowances we identified important biomarker differences between responding and non responding patients enabling the emerge and select trials. Next the exciting data from ICONIC at AACR where we showed improved responses progression-free survival and overall survival directly linked to the treatment-emergent ICOS hi CD4 T cells.
These cells are a vopra-associated pharmacodynamic biomarker not seen with PD-1 inhibitors. Next the identification of a predictive biomarker TIs vopra to be used for patient selection in upcoming select trial which we believe will allow us to select patients more likely to generate ICOS hi CD4 T cells in the presence of vopra and potentially experience clinical benefit. And the work we've done with dosing and schedule which may be an important feature of how to optimize activity of stimulatory rather than inhibitory based immunotherapies. As we look to 2020 the significant unmet need faced by many cancer patients continues to be at the forefront of everything we do. Beth will take you through more details on both EMERGE and SELECT in a moment. But before turning the call over to her I'd like to take this opportunity to reflect on the unmet need vopra could have a major impact starting in non-small cell lung cancer. The last decade has been very exciting with game-changing treatment advances in oncology made by approved checkpoint inhibitors. As PD-1 inhibitors expand further and further into frontline therapy a growing number of patients who have progressed on these therapies need new treatment options. For example we estimate approximately 90% and of non-driver mutation frontline non-small cell lung cancer patients in the U.S. receive a PD-1 or PD-L one inhibitor as part of their initial therapy.
And the majority of those patients either relapse or do not respond creating a new growing area of unmet need. Standard of care for this patient population is docetaxel which has a low response rate and the challenging toxicities associated with chemotherapy. Part of the vote provision is to provide better treatment options for patients in this setting. And that market opportunity is substantial. With more than 40000 patients in the U.S. each year in just this particular setting. We continue to believe that novel approaches that are independent of the PD-1 inhibitor CD8 focused biology will be required to derive meaningful benefit in the growing population of patients who progressed on PD-1 inhibitors. Fundamental immunology research over the decades emphasize the importance of CD4 T cells and their central role in orchestrating a more complete overall immune response and speaks to the potential opportunity for vopra. Our vopra strategy is highly differentiated from the majority of other studies in this patient population most of which employ retreatment of patients who have already progressed on a PD-1 inhibitor with a PD-1 inhibitor again along with another agent. In the PD-1 inhibitor naive population the use of a predictive biomarker may support improved outcomes in a chemo-free immunotherapy combo regimen.
As we recently presented our upcoming select trial uses the TIs vopra biomarker to select patients for treatment with vopra plus our PD-1 inhibitor JTX-4014. We believe TIs vopra positive patients at baseline have a higher likelihood of generating ICOS hi CD4 T cells in the presence of vopra and that's a potentially greater chance of clinical benefit. Beyond our clinical programs we continue to make progress advancing our earlier-stage pipeline using our translational science platform. We continue to believe that our strategy of discovery and developing IO therapies aimed at immune cell types beyond the traditional CD8 cell is an area of opportunity to bring more benefit to patients. Notably we advanced our next development candidate to come from our platform JTX-1811 which is currently an IND-enabling activities and is on track for first half 2021 IND filing. JTX-1811 is a monoclonal antibody engineered to deplete tumor resident T regulatory cells. While sparing other types of T cells.
We tried to present additional scientific data supporting the development of JTX-1811 at the upcoming AACR meeting in April. On the corporate development front we demonstrated external validation with the out-licensing of our macrophage candidate JTX-8064 to celgene. That was part of a broader renegotiation with Celgene and we now have the full unencumbered global rights to vopra JTX-4014 GTX-1811 and our entire discovery pipeline. On the heels of a strong 2019 of pipeline execution and corporate development we are poised for an important year of new clinical data and key milestones in 2020. To reiterate we plan to report preliminary efficacy and related biomarker data for vopra from the IMERGE trial in the second half of 2020 initiate the SELECT trial using TIs vopra in mid-2020 present data on JTX-1811 at the 2020 AACR meeting continue IND-enabling activities for JTX-1811 with an expected IND filing in the first half of 2021 and continue to work on advancing multiple new targets from our discovery pipeline.
With that I'll now turn the call over to Beth to further discuss our clinical pipeline and science in more detail.
Elizabeth Trehu, M.D. -- Chief Medical Officer
Thanks Rich and good morning everyone. As Rich mentioned 2020 is an important year of new clinical data and key milestones for Jounce building on our key clinical learnings in 2019. Beginning with our vopra program we continue to make significant progress and have introduced two different development paths based on our reverse translational analyses. The first approach is our induction strategy in the EMERGE trial; and the second is our patient selection strategy in the SELECT trial using our predictive biomarker TIs vopra. Both EMERGE and select trials are based on three major learnings from ICONIC. First we identified treatment-emergent ICOS hi CD4 T cells in the peripheral blood of patients treated with vopra alone or in combination with nivolumab that are associated with clinical benefit including response rate progression-free survival and overall survival. We've shown that emergence of these cells does not occur with PD-1 inhibitor therapy and therefore we believe that they are vopra-specific cells. We have also demonstrated that ICOS hi CD4 T cells expand and persist throughout durable responses some over two years. Second we identified an RNA signature in baseline tumor biopsies which we call TIS vopra which is optimized for prediction of emergence of ICOS hi CD4 T cells and predicted clinical benefit in ICONIC. And third we identified what we believe is a more optimal dosing regimen for vopra.
All of our vopra trials are built upon the fundamental science of our founders coupled with the reverse translational analyses from our ICONIC trial. Another key learning has been that vopra activity requires the presence of primed ICOS hi CD4 T cells. All of this work has culminated in our two vopra development paths. First the induction path in which ICOS hi CD4 T cells are induced by another agent prior to administration of vopra. The study for the induction path is the EMERGE trial which is a Phase II open-label multicenter trial using ipilimumab or ipi to induce ICOS hi CD4 T cells prior to vopra administration. The trial is under way in PD-1 experienced patients with non-small cell lung cancer. As Rich mentioned this is an area of high unmet need as PD-1 inhibitors have moved into frontline settings. As we have detailed previously we are implementing a new combination dosing strategy for the EMERGE and SELECT trials which we believe is more appropriate for an agonist. Given our understanding of the kinetics of induction and expansion of ICOS hi CD4 T cells by ipi and vopra respectively we believe that the unique combination dosing and sequencing strategy that we are using in EMERGE optimizes both ICOS hi CD4 T cells and co-stimulatory biology. We believe JOunce has a compelling and differentiated approach to immuno-oncology combination therapy.
We expect to report data from the EMERGE trial including preliminary efficacy and biomarker relationships to clinical outcomes for up to 40 non-small cell lung cancer patients in the second half of 2020. The study investigating the predictive biomarker path is the SELECT trial. Based on the evaluation of baseline tumor samples from patients in ICONIC we identified the gene signature and threshold to store which predicts rope associated ICOS hi CD4 T cells emergence as well as improved response rate overall survival and six and nine month progression-free survival in TIS vopra positive patients. The SELECT trial is designed to determine if patients with TIS vopra positive tumors will have a higher likelihood of generating ICOS hi CD4 T cells T cells in the presence of vopra resulting in potentially greater clinical benefit. TIS is an 18-gene signature that was originally developed as a predictive biomarker for PD-1 inhibitors. However TIS also includes genes associated with integral elements of CD4 T cell biology that may contribute to a more comprehensive immune response. In the upcoming Phase II select trial patients will be selected using TIS vopra. SELECT is a randomized ex U.S. trial in non-small cell lung cancer comparing vopra plus JTX-4014 RPD-1 inhibitor to JTX-4014 alone. We expect to enroll approximately 75 immunotherapy naive second line non-small cell lung cancer patients who will be selected using the TIs poker biomarker.
We estimate that approximately 20% of second-line non-small cell lung cancer patients will be above the h-hh. TIs for threshold and potentially eligible for the trial. We expect to initiate the select trial in mid-2020 and report interim clinical data in 2021. Turning to JTX-4014 we presented Phase I safety and preliminary efficacy data at the 2019 SITC meeting in November. Of note antitumor activity was observed with an overall response rate of 16.7% including one complete response and two partial responses all confirmed resist responses and with an acceptable safety profile in a difficult-to-treat population with no therapeutic options. Using our own PD-1 inhibitor in combination with vopra provides flexibility and cost savings. I'm proud of the accomplishments of our team in 2019 and look forward to continued progress in 2020 on clinical trial execution and readouts on clinical and biomarker data.
Now I would like to turn the call over to Tim for a discussion of our year-end financial results. Kim?
Kim Drapkin, CPA -- Chief Financial Officer
Thanks Beth and good morning everyone. As we reported in this morning's press release we ended 2019 with cash cash equivalents and investments totaling $170.4 million compared to $195.9 million for 2018. The decrease was primarily due to operating costs incurred during the year offset by the $50 million license fee received in July 2019 pursuant to our JTX-8064 license agreement with Celgene. Turning to the P&L. Our license and collaboration revenue was $147.9 million for full year 2019 compared to $65.2 million for 2018. The year-over-year increase includes $50 million of cash received under the JTX-8064 license agreement with Celgene and $97.9 million of noncash revenue recognition related to the Celgene upfront payment of $225 million that we received in 2016. During 2019 we incurred $67.1 million in research and development expenses compared to $70.1 million for 2018. The decrease in R&D expenses for the full year 2019 was due to $6 million of decreased manufacturing and IND-enabling costs and $0.9 million of decreased lab consumable costs. The decrease was partially offset by $3.1 million of increased employee compensation costs. General and administrative expenses were $27.9 million for 2019 compared to $26.4 million for 2018. The increase in G&A expenses is primarily the result of increased employee compensation costs.
Net income for 2019 was $56.8 million or basic net income per share of $1.72 and diluted net income per share of $1.66 as compared to a net loss of $27.4 million in 2018 or a basic and diluted net loss per share of $0.84. This increase was driven by the $147.9 million of license and collaboration revenue recognized under our agreement with Celgene. We reiterate the 2020 financial guidance we provided in January. We continue to expect gross cash burn on operating expenses and capital expenditures for the full year 2020 to be approximately $80 million to $95 million. We are no longer providing license and collaboration revenue guidance as potential future payments under our JTX-8064 license agreement with Celgene our royalty and milestone based. Given the strength of our balance sheet we expect our existing cash cash equivalents and investments to be sufficient to enable the funding of our operating expenses and capital expenditure requirements through the end of 2021. Additionally we continue to have the flexibility to drive our innovative immunotherapy pipeline while efficiently executing against our strategic plans and goals.
With that I'll hand the call to Rich for a final thought.
Richard Murray, Ph.D. -- Chief Executive Officer and President
Thanks Kim. Before we open the call for questions I'd like to bring the conversation back to the patients that we're trying to help. The success of the initial checkpoints has created benefit for patients where none was not possible less than a decade ago. But with that new challenges and therefore opportunities have arisen to treat patients who've progressed on PD-1 inhibitors in broader topic of moving IO therapies closer to a precision medicine concept. I believe our new trials reflect the scientific advancements that will need to be made from data gleaned from the lab and the clinic so that we can continue to envision a future with longer and broader durable benefit for patients that do not have those options today. As we look forward to updating you in the future.
And with that we'd now like to open the call for your questions. Operator?
Questions and Answers:
Operator
[Operator Instructions]. Your First question comes from the line of Boris Speaker from Cowen Your line is open.
Boris Speaker -- Cowen -- Analyst
Good morning, Congratulations on all the progress. So question number one on the merge trial are you selecting out patients that don't show ICOS hi CD cells from IP induction? And maybe kind of a little more broadly what is the dosing in the EMERGE trial? And does it make sense to add an ipi booster in the middle of treatment.
Elizabeth Trehu, M.D. -- Chief Medical Officer
Sure. So I'll start with the second question. So the dosing is it is given every six weeks for up to four doses alternating with vopra so you get it on day one and three weeks later the patients get vopra. And then three weeks later they get another dose of ipi then vopra. So we do that alternating sequence for up up to four doses of ipi after which they receive vopra alone. So in terms of the ICOS CD4 cells it's a really interesting question. So we are tracking those cells very closely. So we're watching what they do after ipi and then before vopra and then after ipi again. Right now we're not doing any kind of selection. But we are following that very carefully and it certainly is something to think about in the future. We also although we're not using any selection in this study. We have we are testing a number of potential predictive biomarkers in baseline tumor samples that we'll be able to go back and look at. So right now the strategy is to induce the ICOS CD4 cells with vopra with it sorry and then to treat with vopra which as we expect to cause proliferation sustained activation of those cells over time which in our iCONIC study was associated with long-term clinical benefit.
Boris Speaker -- Cowen -- Analyst
Got you. My last question on the TIS vopra a biomarker test. If the SELECT trial is successful it looks like a very useful biomarker. What would you have to do to make the test approval by the FDA?
Elizabeth Trehu, M.D. -- Chief Medical Officer
Sure. So it's already a validated test so it's run on the nanostring platform. And there's just there's a series of steps to go through to create a companion diagnostic. And we've already mapped out what that path would look like. We would work with a vendor that would actually be the one to develop the companion diagnostic in partnership with us on our clinical trial.
Boris Speaker -- Cowen -- Analyst
So it wouldn't be limiting in terms of the regulatory strategy to do? that's all I wanted to know...
Kim Drapkin, CPA -- Chief Financial Officer
No. No no not at all.
Boris Speaker -- Cowen -- Analyst
Right. Thank you very much for taking my questions.
Kim Drapkin, CPA -- Chief Financial Officer
You're welcome.
Operator
Your next question comes from the line of James Birchenough Alfaro Your line is open.
James Birchenough -- Alfaro -- Analyst
Hi, guys. Thanks for all the details for taking the questions. A couple. So just on the EMERGE study is there any early insights you have on the tolerability of the modified dosing protocol that you're pursuing? And any early indication of success at induction about ICOS hi CD4 T cells with ipi. And then maybe related to that is there a predictive rate of ipi induction how reliable is it the induction of like those high CD4 cells? And then I've got a follow-up.
Elizabeth Trehu, M.D. -- Chief Medical Officer
Sure. So all I can really tell you right now is enrollment is on track to support the interim analysis that we're planning to do later this year and that's when we'll report data. So we don't typically provide any information on data from the ongoing trial. As I said enrollment is going well and we're on track to have data in the second half of the year. And then to your other question...
James Birchenough -- Alfaro -- Analyst
J Just thinking about historical date on ipi for ICOS hi CD4 T cell for.
Elizabeth Trehu, M.D. -- Chief Medical Officer
Sure So it's a little hard to interpret sometimes. We've heard people say that all the cells get induced ICOS gets induced on all the cells but then it drops off very quickly. So it's a little bit hard to discern from the literature exactly what the expected rate of ICOS induction from just it would be. But of course our trial will answer that because we are measuring that in a prospective manner. Most of the studies in which that's been done it's been more of a retrospective finding so I think ours will be the first study to my knowledge that's prospectively looking at how the kinetics of ICOS induction after ipi and then with vopra added on.
Richard Murray, Ph.D. -- Chief Executive Officer and President
Yes what is published Jim and they tend to be a fairly decent number of small studies but with kind of a common theme to that and that tends to be done in PD-1 naive patients. And of course we're looking at a PD-1 experience. But from that kind of collection of small studies the numbers are always north of 50%. Some will claim almost all the patients but really what we think is extremely important is the maintenance and sustainability of these cells. And that's what we think our trial will be able to uniquely answer.
James Birchenough -- Alfaro -- Analyst
And then just one final question. Just on the SELECT study and what you learned from ICONIC. Were there other RNA signatures that you evaluated? Or was this the one that you prospectively thought would make sense and really the only one you evaluated? Just wondering if there were other RNA signatures that had a decent predictive value.
Elizabeth Trehu, M.D. -- Chief Medical Officer
Sure. So we actually we had a long list of genes that we looked at and a number of pre determined signatures that we assess. And this one came out as the one that looks the most predictive for clinical benefit. But then what we thought was really really important was to see if it also tracked with the ICOS hi CD4 T cells T cells. And so first it looked like it predicted clinical benefit. But since many of these patients were also treated with a PD-1 inhibitor we then took this biomarker and applied it to see its predictive value for ICOS hi CD4 T cells emergence and then it clearly predicted for that. And then we selected the threshold based on the ability to predict ICOS hi CD4 T cells. And then when we apply that to the clinical data it was clearly also predicted for clinical benefit. But yes we looked at a number of different genes isolated genes and gene signatures prospectively and this was the one that appeared to be the best.
James Birchenough -- Alfaro -- Analyst
Great, thanks for taking the questions.
Elizabeth Trehu, M.D. -- Chief Medical Officer
You're welcome.
Operator
Your next question comes from the line of Michael from Baird Your line is open.
James Birchenough -- Alfaro -- Analyst
Hey, guys, thanks for taking the question. Just another one on EMERGE and in terms of the interim update expect in the second half of this year. Can you just give us a sense of what types of biomarker data you plan to provide?
Elizabeth Trehu, M.D. -- Chief Medical Officer
Sure. Definitely the ICOS hi CD4 T cells target engagement since we're doing a new dosing schedule that other than what we've done before. So those are the two primary ones. We also as I said we plan to do some relooking at some baseline biomarkers and some other aspects of biology.
Michael -- Baird -- Analyst
Got it. And maybe just in terms of patient numbers you've mentioned potentially up to 40 patients. But can you maybe give us a sense of sort of average follow-up at that point in time. Just trying to get a sense of how meaningful?
Elizabeth Trehu, M.D. -- Chief Medical Officer
Yes. Yes yes absolutely. So yes so we've timed the interim analysiS to be done after every subject has had at least two post-treatment or on-treatment CT scans. So we'll have at least 18 weeks of data on all of those patients before we report any data.
Michael -- Baird -- Analyst
Okay, great. Thank you.
Elizabeth Trehu, M.D. -- Chief Medical Officer
You're welcome.
Operator
Your next question comes from the line of Debjit Chattopadhyay for H.C. Wainwright Your line is open.
Aaron Welch -- H.C. Wainwright -- Analyst
This is Aaron on for Debjit. So I have some questions about how you plan on tackling the enrollment challenges for the SELECT trial like given COVID-19 disruptions? And how do you expect enrollment to go in the SELECT study given that many of the non-small cell lung cancer patients are likely to have previously been treated with an anti-PD-1?
Elizabeth Trehu, M.D. -- Chief Medical Officer
Sure. So we're doing this study ex U.S. because there actually are many countries in which there's very limited access to the PD-1 inhibitors that are approved in this country. So there are places where patients are anxious to enroll in a clinical trial to be able to get access to a PD-1 inhibitor. So we're really happy that we're providing them with that opportunity. Regarding the challenges of enrollment probably the biggest challenge is posed by having a requirement for a selective biomarker. However if you think about some selective biomarkers like ALK or VET where you're talking about 3% to 7% of a population we estimate that the TIS vopra will select about 20% of the second line non-small cell lung cancer patients. And in our conversations with investigators 20% is they're very comfortable with screening one inside of their patients is likely to be positive for the trial. So we have a number of different strategies in place to tackle this. We have enough sites and have a a strategy to screen for patients in a way to enable us to enroll those 75 patients and have data preliminary data in 2021.
Richard Murray, Ph.D. -- Chief Executive Officer and President
And maybe could I jump in there. Sorry to interrupt Aaron just to be clear the study is on IO naive patients not PD-1 experienced patients ex U.S. right.
Aaron Welch -- H.C. Wainwright -- Analyst
Right. And just real quick will could we expect to see any TIS vopra evaluations of patients coming out of the EMERGE study?
Elizabeth Trehu, M.D. -- Chief Medical Officer
Yes. We are looking at tippin baseline samples in the EMERGE study as well as well as other predictive biomarkers but that's obviously the one that we're the most interested in right now.
Aaron Welch -- H.C. Wainwright -- Analyst
Okay, thank you.
Elizabeth Trehu, M.D. -- Chief Medical Officer
Thank you. You're welcome. [Operator Instructions] Your next question comes from the line of Steve Seedhouse from Raymond James Your line is open.
Daniel H. McMahon -- Raymond James -- Analyst
This is Daniel on for Steve. So some checkpoint inhibitors are approved in PD-L1 expressing patients after showing greater benefits in those populations compared to those that do not express PD-1 and that you have a biomarker for ICOS hi what are your thoughts on targeting patients that are both PD-L1 and also have biomarkers for ICOS hi.
Elizabeth Trehu, M.D. -- Chief Medical Officer
Sure. So if you recall that this was originally developed as a predictive biomarker for PD-1 inhibitors. So we do actually expect the data with JTX-4014 in the SELECT study to be potentially better than in an unselected PD-1 naive second line non-small cell lung cancer patient group. We will be looking at PD-L1 scores baseline as well in that study. And so that should give us a good sense of how much overlap there is the TIS vopra's threshold that we've selected should allow us to demonstrate at least the trial is designed to demonstrate the superiority of vopra plus 4014 versus 4014 alone. But you're asking a very important question. If the study is positive and we want to take this combination forward it is very important for us to understand how it would compare to a PD-L1 selection criteria. And so we will generate that data from the study. Which will be very important to inform the development path forward. As we've said we believe this study would position vopra as really the combination partner of choice with a PD-1 inhibitor in a selected patient population as we know that vopra date has not added any toxicity to the PD-1 inhibitor alone and therefore it will be a very nice IO combination chemo-free combination for patients in many different tumor types. And Rich do you want to add something?
Richard Murray, Ph.D. -- Chief Executive Officer and President
Yes. Yes maybe just adding a comment to that. So the way to look at the biomarker TIS vopra selection is you we expect the enrichment for PD-1 response. As that says we need to look at that and link that to PD-L1 standing in terms of the magnitude of that but we expect that. But then on top of that we've kind of built-in this threshold for the ICOs high at CD4 cell detection. So we're kind of tuning on top of that to score for the combo. And hence the randomized trial that we'll be doing which would be looking at just the PD-1 and then the PD-1 plus vopra. So we think the nature of how the biomarker has been will be utilized fit perfectly with the concept of doing a randomized trial. Okay got it.
Daniel H. McMahon -- Raymond James -- Analyst
I understand. And one quick follow-up question. You mentioned that approximately 20% of second-line non-small cell like cancer patients are estimated to be above the biomarker cutoff. And just to confirm does that number only apply to second-line patients or to the non-small cell population as a whole?
Elizabeth Trehu, M.D. -- Chief Medical Officer
So that's the data that we actually have from nanostring and it's specific to the second line PD-1 naive non-small cell lung cancer patients. So we're working with them to understand the frequency in other areas. But since that's the patient population. We're doing the study in that was our first priority to understand the prevalence in that population.
Daniel H. McMahon -- Raymond James -- Analyst
Okay, thank you for taking our questions.
Elizabeth Trehu, M.D. -- Chief Medical Officer
You're welcome.
Operator
[Operator Closing Remarks]
Duration: 36 minutes
Call participants:
Komal Joshi -- Head of Investor Relations
Richard Murray, Ph.D. -- Chief Executive Officer and President
Elizabeth Trehu, M.D. -- Chief Medical Officer
Kim Drapkin, CPA -- Chief Financial Officer
Boris Speaker -- Cowen -- Analyst
James Birchenough -- Alfaro -- Analyst
Michael -- Baird -- Analyst
Aaron Welch -- H.C. Wainwright -- Analyst
Daniel H. McMahon -- Raymond James -- Analyst
